Loading...

Longeveron Inc.

LGVNNASDAQ
Healthcare
Biotechnology
$0.68
$-0.01(-2.13%)

Longeveron Inc. (LGVN) Financial Performance & Income Statement Overview

Review Longeveron Inc. (LGVN) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
237.38%
237.38%
Operating Income Growth
21.43%
21.43%
Net Income Growth
25.41%
25.41%
Operating Cash Flow Growth
27.02%
27.02%
Operating Margin
-791.51%
791.51%
Gross Margin
82.29%
82.29%
Net Profit Margin
-760.63%
760.63%
ROE
-85.06%
85.06%
ROIC
-97.17%
97.17%

Longeveron Inc. (LGVN) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Longeveron Inc. LGVN financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$381000.00$603000.00$773000.00$468000.00
Cost of Revenue$106000.00$73000.00$91000.00$124000.00
Gross Profit$275000.00$530000.00$682000.00$344000.00
Gross Profit Ratio$0.72$0.88$0.88$0.74
R&D Expenses$2.52M$1.99M$2.21M$1.72M
SG&A Expenses$2.94M$2.82M$3.13M$2.12M
Operating Expenses$5.46M$4.81M$5.33M$3.84M
Total Costs & Expenses$5.56M$4.88M$5.42M$3.97M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$0.00$242000.00$235000.00$229000.00
EBITDA-$5.18M-$4.04M-$4.41M-$3.27M
EBITDA Ratio-$13.60-$6.70-$5.71-$6.99
Operating Income-$5.18M-$4.28M-$4.65M-$3.50M
Operating Income Ratio-$13.60-$7.10-$6.01-$7.48
Other Income/Expenses (Net)$170000.00$200000.00$81000.00$87000.00
Income Before Tax-$5.01M-$4.08M-$4.57M-$3.41M
Income Before Tax Ratio-$13.15-$6.77-$5.91-$7.29
Income Tax Expense$0.00$0.00$0.00$0.00
Net Income-$5.01M-$4.08M-$4.42M-$3.41M
Net Income Ratio-$13.15-$6.77-$5.72-$7.29
EPS-$0.34-$0.27-$0.32-$0.52
Diluted EPS-$0.34-$0.27-$0.32-$0.52
Weighted Avg Shares Outstanding$14.95M$14.89M$13.63M$6.51M
Weighted Avg Shares Outstanding (Diluted)$14.95M$14.89M$13.63M$6.51M

Financial performance has remained strong, with revenue growing from $468000.00 in Q2 2024 to $381000.00 in Q1 2025. Gross profit continued to perform well, with margins at 72% in the latest quarter. Operating income reached -$5.18M in Q1 2025, holding a steady -1360% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$5.18M. Net income dropped to -$5.01M, keeping EPS at -$0.34. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;